Author:

  • All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Announcements 2025
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

Appointment of Chief Manufacturing & Operations Officer Paiania, September 3, 2026 - LAVIPHARM S.A. announces the appointment of Mr. Anastasios Spyropoulos as Chief Manufacturing & Operations Officer. Mr. Spyropoulos is a Chemical Engineer (BEng, University of Leeds) with postgraduate studies at the National Technical University of Athens....

Announcement Appointment of Chief Quality Officer Paiania, June 11, 2026– LAVIPHARM S.A. announces the appointment of Ms. Katerina Karapa as Chief Quality Officer (CQO). Ms. Karapa holds degrees in Chemistry and Analytical Chemistry (Roger Williams University & Northeastern University, USA) and an Executive MBA from ALBA Graduate...

Flash Note Key Financial Highlights — First Quarter 2026 EBITDA from Continuing Operations Up 11% Paiania, May 28, 2026 — The Lavipharm Group reports an 11% increase in consolidated EBITDA from continuing operations for the first quarter of 2026, which amounted to EUR 3.13 million, compared to...

Paiania, April 27, 2026 – Today, Lavipharm S.A. conducted its Annual Analyst Update in accordance with the Company’s Financial Calendar for 2026. The presentation took place at the Athens Stock Exchange and was organized by the Hellenic Fund and Asset Management Association. In his opening remarks,...

Flash Note: Annual Financial Results 2025 (Unaudited Financial Data) Strong EBITDA Growth of 48.9% and Significant Increase in Earnings Before Tax by 108,2% Paiania, March 19, 2026 - Lavipharm S.A. informs the investment community of the key financial figures for fiscal year 2025. Consolidated Sales from...

Paiania, 05 March 2026 - Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2026, as follows.. FINANCIAL CALENDAR 2026...

Peania, November 17, 2025 – Lavipharm S.A. informs the investment community of the Group’s key consolidated financial figures for the nine-month period of 2025. Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) from continuing and discontinued operations increased by 11.2%, reaching €10.47 million compared...

Financial Results for the First Half of 2025 – Steady Growth Momentum Peania, September 18, 2025 – Lavipharm Group reports an increase in its consolidated sales during the First Half of 2025. Specifically, consolidated sales from continuing operations amounted to €31.0 million, compared to €29.3 million...